Highlight
- ANGPTL4 is a key regulator that inhibits lipoprotein lipase, impacting triglyceride metabolism.
- MAR001, a monoclonal antibody against ANGPTL4, significantly lowers fasting triglyceride levels in adults with elevated triglycerides.
- The phase 2b trial showed dose-dependent reductions in triglycerides up to 45% at 12 weeks, with a favorable safety profile.
- This therapeutic approach may address residual cardiovascular risk associated with hypertriglyceridemia.
Study Background
Specialty calculators
For clinical reference; use professional judgment.